AIQ is changing how clinicians manage complex diseases, starting with late-stage cancer. AIQ develops novel imaging biomarkers that assess and predict a patient’s response to treatment, including both effectiveness and toxicity. The biomarkers provide more comprehensive and accurate information about treatment response than other approaches. Oncologists use AIQ’s technology to make more confident treatment decisions, personalize care for their patients, and improve treatment outcomes. Including future expansion into other diseases, such as neurology and cardiology, the global market opportunity is forecast to exceed $30B by 2027. AIQ’s products are cloud-architected software solutions. The company has offices in Madison, Wisconsin, and Perth, Australia.

Medical device start-up focused on treating dysphagia. Raised $4.4M in capital—including $1.6M non-dilutive grant funding—to grow business. Built supply chain, designed and implemented comprehensive go-to-market strategy, and drove $1.6M in product sales. Secured several new patents, greatly enhancing value of company's IP portfolio. Led complex lobbying effort seeking incremental reimbursement. Ultimately, pivoted company away from medical devices in favor of functional food products, which then represented the highest probability of earning investors a positive return. Worked with the board of directors to put company into "suspended" mode while a third-party agent seeks a licensee for the functional food IP.

Global responsibility for GE's premium anesthesia and respiratory care business with $220M in annual revenue. Charged with maintaining and growing GE's marketing-leading position in anesthesia delivery while simultaneously establishing a strong presence in the ICU. Accountable for P&L performance, global business strategy, product development, portfolio management, business development, and marketing. Direct management of marketing, engineering, clinical, and business development teams including reports in the US, Finland, and India; strong cross-functional influence on sales and operations.

General management of GE's Global Anesthesia Premium Segment, a $160M business. Accountable for P&L performance, global business strategy, product development, portfolio management, business development, and marketing. Direct management of marketing, engineering, clinical, and business development teams including reports in the US, Finland, and India; strong cross-functional influence on sales and operations.

Business responsibility for large medical device development program, reporting directly to the General Manager of the global business. Accountable for ultimate commercial success of the platform of the future. Manage in-licensing of advanced technologies. Provide indirect leadership to large cross-functional team.

Responsible for defining strategy and supporting execution for $274M product business and $128M dialysis services operation. Manage complete Renal product portfolio for all of Latin America and the Caribbean.